Plan

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain

STANFORD, Calif.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at theStanford University School of Medicine have illuminated the pathtaken by human neural stem cells that were transplanted into thebrains of rats and mice, and found that the cells successfullynavigate toward areas damaged by stroke. The research group placed miniscule particles of iron insidestem cells to act as cellular bea...

LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate, LCP-Tacro

Heads into US Phase II Clinical Trials for Organ Transplantation HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ --LifeCycle Pharma announces positive Phase I clinical results forits transplantation product candidate, LCP-Tacro - Heads into USPhase II clinical trials for organ transplantation. Today LifeCycle Pharma A/S (OMX:LCP) announces positive resultsfrom its Phase I cli...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. today announced plans to present the resultsfrom two bremelanotide Phase 2b studies of men with erectiledysfunction (ED). The presenters are Jed Kaminetsky, MD, ClinicalAssistant Professor, Department of Urology, NYU School of Medicine;Stanley E. Althof, PhD,...

King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting

BRISTOL, Tenn.--(BUSINESS WIRE)--May 8, 2007 - KingPharmaceuticals, Inc. (NYSE:KG) announced today that the resultsfrom a Phase III clinical trial for its ALTACE(R) (ramipril)diuretic combination product will be presented at the AmericanSociety of Hypertension's Twenty-Second Annual Scientific Meetingin a poster on Saturday, May 19, 2007 at the Hyatt Regency Hotel,Chicago, Illinois. The pos...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

Argos Therapeutics Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeuticstoday announced the presentation of data on the immunosuppressiveproperties of soluble CD83 at the 7th Joint American Transplantmeeting to be held in San Francisco, May 5-9. The presentationswill be made in collaboration with scientists at the University ofWestern Ontario. "These data suggest that soluble CD83 is able to exten...

Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue

Discovery promises to make retina, spinal cord and other centralnervous system transplants possible BOSTON, April 26, 2007 /PRNewswire/ -- Scientists at theSchepens Eye Research Institute, an affiliate of Harvard MedicalSchool, have identified a key mechanism for successfullytransplanting tissue into the adult central nervous system. Thestudy found that a molecule known as MMP-2 (which is...

Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells

SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - CellerantTherapeutics today announced the publication of data suggestingthat established autoimmune disease can be reversed or stabilizedby the transplantation of purified allogeneic (donated)hematopoietic (blood forming) stem cells (HSC) in a mouse study ofSystemic Lupus Erythematosus (SLE). Subjects that underwent thisprocedure exhibited...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinicaltrial results for heart transplant patients will be released at theupcoming International Society for Heart and Lung Transplantation(ISHLT) 27th Annual Meeting and Scientific Sessions at the HiltonSan Francisco, April 25-28, 2007. Results show promise for efficacyand safety of immunosuppression therapy and lower incidences ofacut...

King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of Altace with Hydrochlorothiazide

BRISTOL, Tenn.--(BUSINESS WIRE)--Apr 19, 2007 - KingPharmaceuticals, Inc. (NYSE:KG) announced today that the Companyhas positive top-line results from the Phase III clinical trialevaluating the efficacy and safety of the Company's ALTACE(R)(ramipril) diuretic fixed-dose combination product. The Company iscontinuing to evaluate the trial data and expects to present thefindings in detail at a...

Isotechnika's independent data monitoring committee conducts review of phase 2b kidney transplant trial

- Company Set to Host Evening Symposium at ATC - EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today thatan independent data monitoring committee (DMC) has met and reviewedthe interim data from the Phase 2b kidney transplant (PROMISE)trial. The review included 3 month data from approximately 1/3 ofthe anticipated 332 patients to be enrolled. The DMC hasrecommended that...